SAT-787 - Romosozumab vs Alendronate and Cardiovascular/Cerebrovascular Events in Osteoporosis: 1-, 3-, 5-Year and Ever-before-Treatment Outcomes in 1,184,957 Patients with and without Prior CVD/Stroke (Trinetx Cohort)

Abstract Poster Presenter(s)

• MN

  Mahmoud Nassar, MD, PhD, MSc, MHA, MPA, CPHQ, SSBB.

  Assistant Professor of Medicine
  THE UNIVERSITY OF VERMONT MEDICAL CENTER INC.
  Williston, United States

Senior Author/Primary Investigator(s)

• MN

  Mahmoud Nassar, MD, PhD, MSc, MHA, MPA, CPHQ, SSBB.

  Assistant Professor of Medicine
  THE UNIVERSITY OF VERMONT MEDICAL CENTER INC.
  Williston, United States

Co-Author(s)

• MS

  Mariel Sullivan, MD

  University of Vermont Medical Center
  Burlington, Vermont, United States
• ON

  Omar Nassar
• JK

  Jennifer J. Kelly, DO, FACE, CCD

  Division Chief, Endocrinology and Diabetes
  University of Vermont Health
  South Burlington, Vermont, United States